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 Perinatal stem cells research attracted great interest wo-
rldwide in recent years. Foetus-associated tissues contain 
various populations of stem cells, most of which are com-
prised within the category of mesenchymal stem cells 
(MSCs). This special issue collects both reviews and original 
reports on all the perinatal stem cell types which are cur-
rently under investigation. These cells have multiple promis-
ing features: differentiative capacity towards mature cell 
types of all the three germ layers, hypoimmunogenicity in 
vitro and in vivo, ease of sourcing, ex vivo culture and stor-
age. In particular, immune modulation is viewed as a prom-
ising feature of many MSCs populations, since these cells, 
once administered therapeutically, may be able to overcome, 
or at least evade, the host immune response which may lead 
to acute or chronic rejection of the transplant [1]. 
 In the first paper of the issue, Silini et al. discuss the 
therapeutic potential of amnion-derived cells for the treat-
ment of inflammation and fibrosis [2]. In particular, the 
authors did analyze the published literature on the potential 
effects of the amnion and its cellular components within the 
inflammatory-fibrotic scenarios which are featured in several 
diseases, and the factors that could be involved in the ob-
served immunomodulatory actions. Moreover, based also on 
their previous seminal works, the authors compared the dif-
ferent disease indications of human amnion so far, as well as 
describing the major anti-inflammatory and anti-fibrotic 
molecules secreted by amniotic cells. 
 Between the disease indications of amnion-derived cells, 
liver disorders occupy a preminent position. Orthotopic liver 
transplantation is still the obliged clinical treatment for end-
stage diseases, even if the shortage of donor livers and the 
lack of a reliable intra- or extra-hepatic cellular source to 
derive mature hepatocytes, are key elements which push  
ahead the research on this topic [3, 4]. To this regard, Vagh-
jiani et al. comprehensively reviewed the use of placenta- 
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derived stem cells for hepatocyte-like cells derivation and 
transplantation [5]. The authors summarized the literature 
related to the differentiation of human placental stem cells 
into hepatocyte-like cells (both in vitro and in vivo) and on 
the characterisation of the differentiated cells. In addition, 
conspicuous room is dedicated to the experiments aimed to 
testing the functionality of the hepatocyte-like cells in pre-
clinical animal models of liver disease. The authors also ana-
lyzed the biomaterials used for culturing and transplantation 
of these cells into extra-hepatic sites. 
 Regenerative medicine approaches for central and pe-
ripheral nervous system diseases represent a challenging and 
viable option for perinatal stem cells [6, 7]. In this issue, 
Vawda and Fehlings reviewed the current state of the use of 
mesenchymal stem cells in spinal cord injury (SCI) therapy, 
and the future perspectives [8]. In particular, the authors ana-
lyzed in vitro studies and in vivo models which collectively 
suggest that mesenchymal or stromal cells, regardless of 
derivation, may act through the provision of trophic support 
and inflammatory modulation. The authors also summarized 
the potential molecular mechanisms behind these effects. As 
recognized by the authors, the use of perinatal stem cells in 
the most recent clinical trials for SCI is growing reaching 
that of BM-MSCs which currently top the list. As also sug-
gested by the authors, the potential of perinatal MSCs has to 
be fully exploited in terms of definition of their secretome, 
since the bioactive compounds secreted by these cells are 
viewed as the main agents of their beneficial effects in SCI 
and other central nervous system diseases [8]. 
 Cardiovascular diseases are another key clinical option 
for perinatal stem cells. Post-infarct chronic heart failure and 
myocardial infarction represent complex diseases where not 
only the number of functional myocytes is reduced, but also 
the biology of other key populations, as endocardial endothe-
lial cells, is noticeably modified, contributing to the so-called 
"endothelial dysfunction" [9, 10]. Despite the great research 
efforts of the last years, which allowed the characterization 
of heart-resident stem/progenitor cells, also with features of 
MSCs [11, 12], the vast range of biological actions of perina-
tal stem cells strikingly emerges as a valuable option. In the 
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last review paper of this special issue, Corrao et al. analyzed 
the literature on the use of different stem cell populations for 
cell therapy of heart diseases, making the case for Wharton’s 
jelly cells (WJCs) as capable to provide key support to the 
failing organ in terms of expression of immunomodulatory 
molecules and ability to differentiate towards cardiomyo-
cyte-like cells [13]. The consensus of most studies and clini-
cal trials is that the effects of MSCs administration in heart 
diseases are mainly of brief duration: to this regard, in the 
first original paper of this special issue, Lopez and co-
workers did compare the long-term effects of cellular ther-
apy in a myocardial infarction (MI) rat model, by using both 
BM-MSCs and WJ-MSCs [14]. In particular, WJ-MSCs 
were able to form beating cells after coculture experiments in 
vitro, and when applied in vivo, a significant improvement in 
ejection fraction was seen in animals that received MSCs at 
25 to 31 wks time-points after injection. Collectively, the 
authors presented results which are in agreement with previ-
ous reports, with the additional promising evidence that the 
beneficial effects on cardiac functions are durable, thus in-
creasing the potential importance of WJ-MSCs in cell ther-
apy for MI. 
 A further research paper by Balci and Can explored the 
efficiency of different cryopreservation conditions for WJ-
MSCs storage [15]. This is an important point since the main 
prospected use for these cells is as allogeneic "off the shelf" 
therapeutic option, when stored in dedicated tissue banks 
[16]. The authors analyzed the outcomes of different meth-
ods, as computer-controlled multi step slow freezing and 
vitrification, and assessed the maintenance of the key pheno-
typycal features of WJ-MSC (expression of "core" MSC 
markers and HLA-DR) upon de-freezing and culture. Their 
data strongly point to slow freezing as the best method with 
the addition of dimethylsufoxide or sucrose depending on the 
rate chosen for the freezing program [15]. 
 Several reports highlighted that stem cells can be found 
in the human amniotic fluid throughout gestation. Amniotic 
fluid stem cells (AFSCs) are free of ethical constrains, can 
be readily isolated during prenatal diagnostic procedures, 
and showed promising features for regenerative medicine 
applications [17, 18]. In this issue, Moschidou et al. pre-
sented novel results on the molecular profile of AFSCs. In 
particular, authors investigated whether 1
st and 2nd trimester 
c-KIT+ AFSCs could show similar gene expression profiles 
[19]. As reported, even if both populations are clearly re-
lated, differences have been recorded in cell-specific gene 
expression signatures, which comprise 366 genes for 1st tri-
mester and 340 genes for 2nd trimester AFSC. These data 
suggest that the phenotype of AFSCs populations is evolving 
during fetal development, with a reverse correlation between 
lower levels of genes associated with the undifferentiated 
state and higher levels of genes involved in the specification 
of cells and tissues [19]. In our opinion, banking of these cell 
populations and the development of future applications will 
benefit from these new data, which may push forward the 
research of other groups involved in the same topic. 
 Multipotent MSCs (along with the CD34+ hematopoietic 
stem cells) are also present within human umbilical cord 
blood (hUCB). The adherent fraction of hUCB cells consti-
tutes the subpopulation enriched in MSCs. In this issue, 
Grabowska et al. tested the myogenic potential of adherent 
fraction of human umbilical cord blood cells (adhUCBs) 
[20]. Interestingly, adhUCBs cells expressed Pax7 and myo-
genin, suggesting their myogenic potential. The authors also 
showed that muscles injected with adHUCBs cells had 
higher muscle mass when compared with controls. In con-
clusion, this paper represents a first evidence of the potential 
use of adherent fraction of hUCB cells as myogenic cells. 
 Immune features of MSCs evidenced these cells as po-
tential off the shelf therapeutics for many diseases. The 
range of immune-related molecules which are expressed by 
these cells grows constantly [21, 22]. However, only few 
reports do exist in the literature concerning the immuno-
genicity of differentiated cells with respect to the features of 
the undifferentiated parental cells. To this regard, Tee et al. 
present a research paper which deals with the differentiation 
of amniotic epithelium cells (AECs) towards hepatocyte-like 
cells (HLCs), and the functional and immune features of the 
same [23]. Naïve hAEC have low immunogenicity and exert 
immunomodulatory effects that may facilitate allogeneic 
transplantation [24]. The authors found that AEC-derived 
hepatocyte-like cells showed immunomodulatory properties 
and inhibited mitogen induced PBMCs proliferation in vitro, 
similarly to undifferentiated cells. The authors also reported 
that, similarly to what happens in AECs, IFN- challenge 
results in elevation of class I HLA and CD40, as demon-
strated for other stem cell populations, modifying the in vitro 
immunogenicity of HLCs [23]. Therefore as also the authors 
stated, in vivo studies on animal models of acute and chronic 
liver diseases will be needed to assess the functionality, im-
munomodulatory effects and immune responses by the re-
cipient to the HLCs in animal models of acute and chronic 
liver failure to explore the utility of HLCs for allogeneic 
transplantation. Moreover, in our opinion, further studies 
may be encouraged to assess the maintenance of the immu-
nomodulatory features of undifferentiated stem cells also in 
the differentiated progeny of other stem cell types. 
 To this regard, Anzalone et al. [25] present an in vitro 
study on the expression of immune-related molecules in un-
differentiated WJ-MSCs and their differentiated progeny, 
after osteogenic, adipogenic and chondrogenic differentia-
tion. This is a further seminal work on this topic where the 
authors demonstrated for the first time that differentiated 
WJ-MSCs do maintain the HLA setting of the parental cells, 
also for the non-classical type I MHC molecules as HLA-E, 
HLA-F and HLA-G. In addition, the differentiated cells did 
not upregulate the expression of the B7 co-stimulators CD80 
and CD86, while maintaining the expression of the immu-
nomodulatory molecule CD276 (B7-H3). The findings are 
useful in better defining the immune phenotype of WJ-
MSCs-derived cells, and in particular for the use of these 
cells in musculoskeletal diseases therapy [26]. 
 In conclusion, the papers of this special issue do provide 
key references to the scientists in the field by both critical 
revision of the literature in selected topics, and providing 
new advances which further encourage research on the po-
tential of perinatal stem cells. 
 In our opinion, what emerges from these reports is that 
on one hand there is the need of pushing on the in vitro char-
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acterization of these cells, in order to satisfy the requirement 
for safety in cell therapy applications. On the other hand, 
these cells demonstrated maturity also for further challeng-
ing in vivo applications which could provide the definitive 
proof of their usefulness in regenerative medicine applica-
tions. Moreover, the emerging evidence that differentiated 
cells may express the same immunomodulatory molecules 
sets as their undifferentiated counterpart, opens new scenar-
ios in the “side branch” of regenerative medicine which is 
called reparative or support medicine. It can be prospected 
that perinatal stem cells effects may be also related not only 
to direct organ repopulation, but to the supportive action on 
diseased organs. A greater understanding of the bioactive 
components of the secretomes of undifferentiated and differ-
entiated stem cells will enable a more informed use of these 
cells and/or their therapeutic derivatives to target specific 
diseases. It is expected that an immunomodulatory differen-
tiated cell, in vivo, may better overcome host responses, pro-
vide a functional bridging action by replacing the function of 
local diseased cells, and act on the organ microenvironment 
by modifying the underlying pathological condition (e.g. 
chronic inflammation) at the basis of disease. Searching for 
this cell may be the target of researchers worldwide, and we 
are convinced that the perinatal tissues may host stem popu-
lations with these features. 
 We are glad and thankful that a panel of renowned scien-
tists, comprising pioneers in the field, has joined our project 
contributing to this special issue on perinatal stem cells con-
tributing reviews on the most recent data on different topics 
that may have a strong impact on the future of regenerative 
medicine, as well as original papers which further move on 
the targets of the use of these cellular populations. It is our 
hope that science reported in this special issue may contrib-
ute to further key developments within this field. 
 We would like to thank the Editor-in-Chief, Prof. An-
thony Atala, for this challenging opportunity and his support 
for the development of this special issue. Finally, we would 
like to thank the editorial staff of Current Stem Cell Re-
search & Therapy, at Bentham Science Publishers for their 
help with the preparation of this special issue. 
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